A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is rather modest. Once again, we are taking in another installment in our “Let’s-see-them-before-they-die” concert series. We also plan to see the Pharmalot ancestors and, otherwise, catch up on some reading. And what about you? This is a fine time to enjoy the great outdoors. Perhaps, this is an opportunity to tidy up around the castle. Or reach out to someone special. Remember, life is short. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Insys Therapeutics (INSY), whose former executive team was arrested for allegedly bribing doctors to prescribe its opioid painkiller, has set aside $150 million to cover a settlement amid ongoing talks with the U.S. Department of Justice, according to a filing with the Securities and Exchange Commission. This does not cover possible deals with various states or other organizations, but suggests a deal with DoJ “may be close at hand,” writes Jefferies analyst David Steinberg.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Given that the “EpiPen Jr” is so new a product, was this just completeness – “the agency received a total of 228 reports of EpiPen or EpiPen Jr. failures during the same time period” – or is the”Jr” significant nexus of failure? The referenced piece gives no clue – and the FDA may not have either but ‘it’s a thought.’

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.